ClinicalTrials.gg
TerminatedNCT05054543Updated Jun 27, 2025

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

A Phase 3 interventional study of Uproleselan and Placebo in Relapsed/Refractory AML, sponsored by Apollomics Inc.. Terminated at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Apollomics Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
In light of the strategic realignment of the company's development focus, it has been determined to discontinue the further development of Uproleselan Injection.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
87th of 433
140 · median 50
Started
2021
with 43 others
Phase 3
54 of 473
25 open now
Registered
149th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 87th largest by enrollment of the 433 interventional ones that give a count, is one of 44 that started in 2021, is one of 54 in phase 3, and was the 149th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Read the detailed description

This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at the time of randomization with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy as described.

Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (\<60, ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse>6 months) and prior HSCT status. Treatment assignment received at randomization will be maintained during all induction and consolidation cycles.

This trial will have the following sequential phases: screening, baseline, induction treatment and count recovery, response assessment, consolidation treatment (if remission is achieved), and follow-up for relapse and survival assessment. Subjects not achieving remission will continue to be followed for long-term trial endpoints such as disease progression and survival. Blinding will be maintained until database lock. This study will carry out long-term follow-up for all subjects for a maximum of 3 years or death of subjects or withdrawal of consent.

03

Conditions studied

  • Relapsed/Refractory AML

Keywords

  • AML
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years and ≤75 years in age
  2. AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis
  3. For subjects with primary AML:

    1. Refractory disease is defined as persistent disease (≥5% blasts in the bone marrow) at least 28 days after initiation of anthracycline-containing induction therapy or relapse from a first remission (CR, CRi, complete remission with incomplete recovery [CRp], CRh) lasting for \<90 days. Isolated extramedullary disease is not allowed.
    2. Persistent disease (≥5% blasts in the bone marrow): Must have received 1 (and only 1) prior anthracycline-containing induction regimen. Except as defined below, a second induction with intent to induce remission is not allowed.

      1. Re-induction within 28 days with a comparable regimen containing the same chemotherapy agents (e.g., cytarabine/daunorubicin '7+3' and '5+2'; or cytarabine/daunorubicin '7+3' and '7+3') is allowed.
      2. Re-induction within 28 days with a comparable regimen using an alternative anthracycline (e.g., cytarabine/daunorubicin in the first induction and cytarabine/idarubicin in the second) is allowed.
      3. Previous induction with certain regimens (venetoclax/hypomethylating agent [HMA], venetoclax/LDAC, single agent HMA) followed by an anthracycline induction regimen is allowed. May have achieved remission with certain regimens (venetoclax/HMA, venetoclax/LDAC, single agent HMA) and then experience relapse now refractory to anthracycline-containing induction.
    3. Relapse from first remission (CR, CRi, CRp, CRh) lasting \<90 days: 1) After achieving first remission from any induction regimen, may have received consolidation before experiencing relapse.
  4. No more than one prior stem cell transplant.
  5. Has not received the chemotherapy regimen to be used for induction on this trial.
  6. Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial.
  7. Peripheral absolute blast count (ABC) ≤40.0 x 109/L (ABC = total white blood cells [WBC] x blast % in peripheral blood). Hydroxyurea to control absolute blast count is allowed prior to uproleselan/placebo dosing.
  8. (ECOG) performance status 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute promyelocytic leukemia
  2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)
  3. Chronic myeloid leukemia with myeloid blast crisis
  4. Active signs or symptoms of CNS involvement by (No lumbar puncture required)
  5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  6. HSCT ≤ 4 months, autologous HSCT ≤ 3 months or donor lymphocyte infusion (DLI) ≤ 6 weeks prior to Uproleselan/placebo dosing.
  7. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing
  8. Inadequate organ function.
  9. Abnormal liver function.
  10. Known active infection with hepatitis A, B, or C, or .
  11. \<45 mL/min (Cockcroft-Gault method) or creatinine >1.5x (any assessed must be within eligibility limit).
  12. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  13. Myocardial infarction within 6 months of uproleselan/placebo dosing, or subject has current significant cardiovascular disease.
  14. Major surgery within 4 weeks before uproleselan/placebo dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Uproleselan

    Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation

    Drug: Uproleselan

  • Placebo comparator
    Placebo (Saline, 0.9% Sodium Chloride)

    Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation

    Drug: Placebo

Interventions

  • A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

    Also known as: GMI-1271

  • DrugPlacebo

    0.9% Sodium Chloride

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time from the date of randomization into the study to the date of death.

    Time frame: 3 years

Secondary outcomes

  1. Remission rate(rate of CR, CR/CRi and CR/CRh)

    Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh

    Time frame: Up to 60 days

  2. Duration of remission

    Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.

    Time frame: Up to 3 years

  3. Event-free survival

    Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.

    Time frame: Up to 3 years

  4. Rate of severe oral mucositis

    Incidence of severe oral mucositis experienced in patients after treatment.

    Time frame: Up to 254 days

07

Study locations

2 sites
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, Tianjin Municipality 300020, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Aug 2024, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Sep 23, 2021
StartActual
Nov 17, 2021
Primary completionActual
Aug 22, 2024
CompletionActual
Aug 22, 2024
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05054543
Lead sponsor
Apollomics Inc.
Responsible party
Sponsor
First posted
Sep 23, 2021
Start date
Nov 17, 2021
Primary completion
Aug 22, 2024
Completion
Aug 22, 2024
Last update
Jun 27, 2025

Study contacts

Jianxiang Wang, PhD
principal investigator · Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Uproleselan

Start the discussion